Gupta Praveen Kumar, Saxena Apoorva
Department of Biotechnology, R.V College of Engineering, Bangalore, 560059 India.
Proc Natl Acad Sci India Sect B Biol Sci. 2021;91(3):495-510. doi: 10.1007/s40011-021-01237-y. Epub 2021 Apr 23.
CCR5-delta 32 homozygous stem cell transplantation for HIV-infected individuals is being treated as a milestone in the global AIDS epidemic. Since 2008, when the second Berlin patient was cured from HIV after undergoing transplantation from a donor with delta-32 mutation, scientists are aiming for a long-term cure for the wider population. In 2019, a London patient became the second person to be free of HIV and came off the antiretroviral drugs completely. CCR5 gene is now being treated as a viable target for HIV treatment. It can be used in the treatment of HIV either through administration of drugs that bind to CCR5 and stop the receptor from working or through gene therapy to alter the CCR5 gene using CRISPR/Cas9 and prevent protein production. This review article aims to identify the obstacles and the need to overcome them in order to bridge the gap between current research and future potential cures for HIV.
CCR5-Δ32纯合子干细胞移植用于治疗HIV感染者被视为全球艾滋病流行中的一个里程碑。自2008年以来，当第二位柏林患者在接受来自具有Δ32突变供体的移植后被治愈艾滋病时，科学家们一直致力于为更广泛的人群寻找长期治愈方法。2019年，一名伦敦患者成为第二个摆脱HIV并完全停用抗逆转录病毒药物的人。CCR5基因现在被视为HIV治疗的一个可行靶点。它可通过以下方式用于治疗HIV：一是使用与CCR5结合并阻止该受体发挥作用的药物，二是通过基因疗法利用CRISPR/Cas9改变CCR5基因并阻止蛋白质生成。这篇综述文章旨在找出障碍以及克服这些障碍的必要性，以便弥合当前研究与未来HIV潜在治愈方法之间的差距。
